Radiopharm Theranostics (ASX:RAD) shows positive results in advanced prostate cancer study

Radiopharm Theranostics reported positive outcomes from a pilot study comparing terbium-161 and lutetium-177 for metastatic castration-resistant prostate cancer.

The study highlights Tb-161's therapeutic index, making it a candidate for advanced cancer treatment due to its unique radiation characteristics.

Radiopharm aims to develop Tb-161 radiotherapeutics targeting prostate cancer and osteosarcoma.

The partnership with TerThera provides exclusive access to Tb-161.